研究报告 Research Report 2 Feb 2026 香港医疗 Hong Kong Health Care 周报（26/1/26-26/1/30）：受资金面影响，板块整体回调，医药流通相对稳健 Weekly Report: Capital pressures drove a broad-based sector correction, with pharmaceutical distribution proving relatively stable [Table_yemei1] 观点聚焦 Investment Focus | [Table_Info] | | | | | --- | --- | --- | --- | | 股票名称 | 评级 | 股票名称 | 评级 | | 百济神州 | Outperform 映恩生物 | | Outperform | | 京东健康 | Outperform 华润医药 | | Outperform | | 药明生物 | Outperform 金斯瑞生物科技 | | Outperform | | 信达生物 | Outperform 国药控股 | | Neutral | ...

研究报告 Research Report 2 Feb 2026 | [Table_Info] | | | | | --- | --- | --- | --- | | 股票名称 | 评级 | 股票名称 | 评级 | | 百济神州 | Outperform 映恩生物 | | Outperform | | 京东健康 | Outperform 华润医药 | | Outperform | | 药明生物 | Outperform 金斯瑞生物科技 | | Outperform | | 信达生物 | Outperform 国药控股 | | Neutral | | 中国生物制药 | Outperform 和黄医药 | | Outperform | | 石药集团 | Outperform 亚盛医药 | | Outperform | | 阿里健康 | Outperform 康诺亚生物 | | Outperform | | 康方生物 | Outperform 再鼎医药 | | Outperform | | 药明合联 | Outperform 时代天使 | | Outperform | | 科伦博泰生物-B | Outperform ...